SCHEMBL3797546

SCHEMBL3797546

[CH2]COC(=O)c1ccc(N=C2C(=O)C3=C(OC(C)(C)CC3)c3ccccc32)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MALT1 Q9UDY8 9/20 0.51
▸ ALDH1A1 P00352 4/20 0.51
▸ MAPT P10636 3/20 0.51
▸ IDO1 P14902 2/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ NPSR1 Q6W5P4 2/20 0.51
▸ KDM4E B2RXH2 2/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ CES2 O00748 1/20 0.51
▸ GMNN O75496 1/20 0.51
▸ TDP2 O95551 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ TP53 P04637 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ GLA P06280 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2D6 P10635 1/20 0.51
▸ HSPD1 P10809 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6033555 0.92 MALT1 (0.53) MALT1ALDH1A1MAPTIDO1SMN1; SMN2
SCHEMBL6033559 0.92 MALT1 (0.53) MALT1ALDH1A1MAPTIDO1SMN1; SMN2
SCHEMBL13123207 0.87 MALT1 (0.47) MALT1ALDH1A1MAPTIDO1SMN1; SMN2
SCHEMBL13123195 0.85 MALT1 (0.47) MALT1ALDH1A1MAPTIDO1SMN1; SMN2
SCHEMBL18774056 0.81 MALT1 (0.65) MALT1ALDH1A1MAPTIDO1SMN1; SMN2
SCHEMBL12473069 0.81 MALT1 (0.65) MALT1ALDH1A1MAPTIDO1SMN1; SMN2
SCHEMBL12473212 0.81 MALT1 (0.68) MALT1ALDH1A1MAPTIDO1SMN1; SMN2
SCHEMBL3797398 0.80 MALT1 (0.41) MALT1ALDH1A1MAPTIDO1SMN1; SMN2
SCHEMBL3797393 0.80 MALT1 (0.41) MALT1ALDH1A1MAPTIDO1SMN1; SMN2
SCHEMBL12473165 0.79 MALT1 (0.61) MALT1ALDH1A1MAPTIDO1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812051-B2 Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential ARQULE, INC. (US) 2010-10-12 — — US disclosed
WO-2006020722-A2 POLYMER CONJUGATES OF BETA-LAPACHONE AND BETA-LAPACHONE ANALOGS FOR TUMOR TARGETING ARQULE, INC. (US) 2006-02-23 — — WO disclosed
US-20060034796-A1 conjugated to polyglutamic acid for enhanced permeability and retention effect ARQULE, INC. 2006-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060034796-A1 conjugated to polyglutamic acid for enhanced permeability and retention effect QPCT, KEAP1, SLC46A1 MALT1 2320/4885ALDH1A1 1063/4885MAPT 2245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback